BNTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BioNTech SE
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 10, 2026
$89.21+1.50 (+1.71%)
Close on Oct 19, 2026
BioNTech SE revenue by segment
By business segment
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Product Sales &External Services | – | – | – | – | – | – | €2.03M | €1.75M | €4.05M | – |
| Clinical | – | – | – | – | – | – | – | – | €623.00K | – |
| Reportable Segments | – | – | – | – | – | – | -€181.52M | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19 vaccine revenues | €2.00B | €2.43B | €3.78B | €17.15B | – | – | – | – | – | 69.5% | -18.0% |
| Revenues from out-licensing | €613.00M | €0 | €0 | – | – | – | – | – | – | 21.4% | – |
| Other revenues | €261.60M | €319.00M | €42.80M | €165.40M | – | – | – | – | – | 9.1% | -18.0% |
| Collaboration Revenues | – | – | – | – | – | – | €84.43M | €101.84M | €42.33M | – | – |
| Collaboration and License Agreement | – | – | – | – | – | – | €84.43M | €101.84M | €42.33M | – | – |
| Other Sales Transactions | – | – | – | – | – | €33.00M | €24.20M | €25.70M | €19.27M | – | – |
| Commercial revenues | – | – | €3.82B | €17.19B | €18.87B | €303.50M | €24.20M | €25.74M | – | – | – |
| Research & development revenues | – | – | €3.50M | €116.00M | €102.70M | €178.80M | €84.40M | €101.84M | – | – | – |
| Bill and Hold Transaction | – | – | – | – | – | – | €1.06M | – | – | – | – |
| Share of Collaboration Partner's Gross Profit | – | – | – | – | – | €188.48M | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | €1.79B | €1.85B | €3.01B | €12.71B | €14.64B | €381.90M | €87.60M | – | – | 62.5% | -2.9% |
| Germany | €759.10M | €706.90M | €482.70M | €3.03B | €2.24B | €31.70M | €11.70M | – | – | 26.5% | +7.4% |
| Ireland | €304.80M | €177.80M | €203.80M | – | – | – | – | – | – | 10.6% | +71.4% |
| Rest of the World | €11.10M | €18.60M | €121.60M | €1.57B | – | – | – | – | – | 0.4% | -40.3% |
| Belgium | – | – | – | – | €675.00M | €56.20M | – | – | – | – | – |
From the segment and revenue-disaggregation notes of BioNTech's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.